PPARA and metabolic dysfunction-associated steatotic liver disease: However, other anti-NAFLD drugs, such as PPAR agonists, thyroid receptor-beta agonist and sirtuin 1 activator failed to do so, which might be explained by their targeting stages (more advanced NAFLD), cell lineages (immune cells), and the most likely, the interspecies bias.